HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose

This article was originally published in The Tan Sheet

Executive Summary

FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court

You may also be interested in...



Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms

A 1final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids will become effective April 12, FDA announced Feb. 6

DSHEA Implementation Action Expected In Second Session Of 108th Congress

A House version of the Dietary Supplement Health & Education Act "Full Implementation" Senate bill is expected early this year, marking the impact of industry efforts to respond to a challenging year in Washington

FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review

FDA's regulatory framework for removing dangerous dietary supplements from the market under the Dietary Supplement Health & Education Act's "unreasonable risk" standard will be issued shortly by the agency

Related Content

Topics

UsernamePublicRestriction

Register

RS127646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel